

# Lung transplant rejection - Pipeline Insight, 2021

<https://marketpublishers.com/r/L464E65C0DA7EN.html>

Date: September 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: L464E65C0DA7EN

## Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Lung transplant rejection - Pipeline Insight, 2021," report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lung transplant rejection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Lung transplant rejection Understanding

#### Lung transplant rejection: Overview

Lung transplant rejection is a common complication after a single or double lung transplant, and it can progress rapidly or subtly. Early diagnosis and management are essential to decrease morbidity and mortality. It is best managed by an interprofessional team approach. Communication and coordination between the patient, the primary clinician, the pulmonologist, and the transplant surgeon in regard to posttransplant testing and follow-up are essential for prevention. Acute lung transplant rejection may increase the risk of a recurrence of acute rejections and the development of bronchiolitis obliterans syndrome.

'Lung transplant rejection - Pipeline Insight, 2021' report by DelveInsight outlays

comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lung transplant rejection pipeline landscape is provided which includes the disease overview and Lung transplant rejection treatment guidelines. The assessment part of the report embraces, in depth Lung transplant rejection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lung transplant rejection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lung transplant rejection R&D. The therapies under development are focused on novel approaches to treat/improve Lung transplant rejection.

## Lung transplant rejection Emerging Drugs Chapters

This segment of the Lung transplant rejection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Lung transplant rejection Emerging Drugs

### TFF TAC-LAC: TFF PHARMACEUTICALS

TFF TAC-LAC is an inhaled dry powder version of tacrolimus, an immunosuppressive drug used in transplant medicine. Tacrolimus is currently the second most commonly administered immunosuppressive drug used in solid organ transplants, despite many challenges for patients and physicians when used for extended periods. Tacrolimus can cause toxicity in the kidneys, particularly when used in high doses. TFF TAC-LAC is a dry powder version suitable for use with a dry powder inhaler. This provides for a high local lung concentration without the problems of an orally dosed tacrolimus.

## Belatacept: Bristol-Myers Squibb

Belatacept is a CTLA4-Ig fusion protein that binds CD80 and CD86 thereby blocking CD28 co-stimulatory signals. Belatacept is a second-generation fusion protein developed by Bristol-Myers Squibb for the prevention of renal and lung transplant rejection.

Further product details are provided in the report.

## Lung transplant rejection: Therapeutic Assessment

This segment of the report provides insights about the different Lung transplant rejection drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players in Lung transplant rejection

There are approx. 7+ key companies which are developing the therapies for Lung transplant rejection. The companies which have their Lung transplant rejection drug candidates in the most advanced stage, i.e. phase II include, Bristol-Myers Squibb.

### Phases

DelveInsight's report covers around 7+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

## Route of Administration

Lung transplant rejection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lung transplant rejection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lung transplant rejection therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lung transplant rejection drugs.

### Lung transplant rejection Report Insights

- Lung transplant rejection Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

### Lung transplant rejection Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

### Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Lung transplant rejection drugs?

How many Lung transplant rejection drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lung transplant rejection?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lung transplant rejection therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Lung transplant rejection and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

TFF Pharmaceuticals

Bristol-Myers Squibb

Zambon SpA

CSL Behring

MimeTech

Roche

Corline Biomedical

Kamada

Quark Pharmaceuticals

## Radikal Therapeutics

### Key Products

TFF TAC-LAC

Belatacept

Liposomal Cyclosporine A

Hizentra

Udonitrectag

Pirfenidone

Renaparin

Alpha-1 antitrypsin

QP LI1

## Contents

Introduction

Executive Summary

Lung transplant rejection: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Lung transplant rejection – DelveInsight's Analytical Perspective

Mid Stage Products (Phase II)

Comparative Analysis

Belatacept: Bristol-Myers Squibb

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Early Stage Products (Phase I)

Comparative Analysis

TFF TAC-LAC: TFF PHARMACEUTICALS

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Preclinical and Discovery Stage Products

Comparative Analysis

Udonitrectag: MimeTech

Product Description

Research and Development



Product Development Activities  
Drug profiles in the detailed report.

Inactive Products

Comparative Analysis

Lung transplant rejection Key Companies

Lung transplant rejection Key Products

Lung transplant rejection- Unmet Needs

Lung transplant rejection- Market Drivers and Barriers

Lung transplant rejection- Future Perspectives and Conclusion

Lung transplant rejection Analyst Views

Lung transplant rejection Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Lung transplant rejection
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Lung transplant rejection
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Lung transplant rejection - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/L464E65C0DA7EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L464E65C0DA7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970